Eversept Partners’s GSK GSK Stock Holding History

Eversept Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,093,700	Closed	-$73.6M	–	70
2022 Q4	$73.6M	Hold	2,093,700	–	–	6.44%	5
2022 Q3	$61.6M	Buy	2,093,700 +850,740	+68%	+$32.2M	5.34%	6
2022 Q2	$67.6M	Hold	1,242,960	–	–	4.81%	7
2022 Q1	$67.7M	Buy	1,242,960 +40,000	+3%	+$2.17M	5.2%	3
2021 Q4	$66.3M	Hold	1,202,960	–	–	4.24%	5
2021 Q3	$57.5M	Buy	1,202,960 +80,000	+7%	+$4.02M	3.97%	7
2021 Q2	$55.9M	Buy	1,122,960 +199,680	+22%	+$9.59M	3.73%	9
2021 Q1	$41.2M	Buy	923,280 +641,200	+227%	+$29.1M	2.13%	10
2020 Q4	$13M	Buy	+282,080	New	+$13M	1.52%	21

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Eversept Partners's GSK Position: Q2 2026 in Review

Eversept Partners reduced its GSK (GSK) stake by 73% in Q2 2026, selling an estimated $68.9M and leaving 481,833 shares worth $25.3M. The position accounts for 1.31% of the portfolio, ranked #18.

Eversept Partners first reported a position in GSK in Q1 2018 and has held it in 34 quarters since. The position peaked at $166M in Q3 2024. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Eversept Partners held 481,833 shares of GSK worth $25.3M as of Q2 2026.
Eversept Partners sold 1,303,342 GSK shares in Q2 2026, an estimated $68.9M.
GSK made up 1.31% of Eversept Partners's portfolio in Q2 2026, its #18 holding.
Eversept Partners first reported a position in GSK in Q1 2018 and has held it in 34 quarters since.
Eversept Partners's GSK position peaked at $166M in Q3 2024.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.